268 related articles for article (PubMed ID: 20542203)
1. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia.
Neuner EA; Casabar E; Reichley R; McKinnon PS
Diagn Microbiol Infect Dis; 2010 Jul; 67(3):228-33. PubMed ID: 20542203
[TBL] [Abstract][Full Text] [Related]
2. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin.
Yoon YK; Kim JY; Park DW; Sohn JW; Kim MJ
J Antimicrob Chemother; 2010 May; 65(5):1015-8. PubMed ID: 20200036
[TBL] [Abstract][Full Text] [Related]
3. agr functionality affects clinical outcomes in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia.
Kang CK; Kim YK; Jung SI; Park WB; Song KH; Park KH; Choe PG; Jang HC; Lee S; Kim YS; Kwak YG; Kwon KT; Kiem S; Kim CJ; Kim ES; Kim HB;
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2187-2191. PubMed ID: 28639163
[TBL] [Abstract][Full Text] [Related]
4. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
Murray KP; Zhao JJ; Davis SL; Kullar R; Kaye KS; Lephart P; Rybak MJ
Clin Infect Dis; 2013 Jun; 56(11):1562-9. PubMed ID: 23449272
[TBL] [Abstract][Full Text] [Related]
5. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
Kullar R; Davis SL; Levine DP; Rybak MJ
Clin Infect Dis; 2011 Apr; 52(8):975-81. PubMed ID: 21460309
[TBL] [Abstract][Full Text] [Related]
6. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
7. [Persistent bacteremia due to methicillin-resistant Staphylococcus aureus. A result of inadequate treatment].
Parra-Ruiz J; Tomas-Jiménez C; Muñoz-Medina L; Hernández-Quero J
Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):372-3. PubMed ID: 19339080
[No Abstract] [Full Text] [Related]
8. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan.
Lin SH; Liao WH; Lai CC; Liao CH; Tan CK; Wang CY; Huang YT; Hsueh PR
J Antimicrob Chemother; 2010 Aug; 65(8):1792-8. PubMed ID: 20511366
[TBL] [Abstract][Full Text] [Related]
12. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Soriano A; Marco F; Martínez JA; Pisos E; Almela M; Dimova VP; Alamo D; Ortega M; Lopez J; Mensa J
Clin Infect Dis; 2008 Jan; 46(2):193-200. PubMed ID: 18171250
[TBL] [Abstract][Full Text] [Related]
13. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
14. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia?
de Sanctis JT; Swami A; Sawarynski K; Gerasymchuk L; Powell K; Robinson-Dunn B; Carpenter CF; Sims MD
Diagn Mol Pathol; 2011 Sep; 20(3):184-8. PubMed ID: 21817905
[TBL] [Abstract][Full Text] [Related]
15. Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients.
Kan LP; Lin JC; Chiu SK; Yeh YC; Lin TY; Yang YS; Wang YC; Wang NC; Yeh KM; Chang FY
J Microbiol Immunol Infect; 2014 Feb; 47(1):15-22. PubMed ID: 23040238
[TBL] [Abstract][Full Text] [Related]
16. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
Clemens EC; Chan JD; Lynch JB; Dellit TH
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
[TBL] [Abstract][Full Text] [Related]
17. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study.
Goldberg E; Paul M; Talker O; Samra Z; Raskin M; Hazzan R; Leibovici L; Bishara J
J Antimicrob Chemother; 2010 Aug; 65(8):1779-83. PubMed ID: 20507860
[TBL] [Abstract][Full Text] [Related]
18. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia.
Yeh YC; Yeh KM; Lin TY; Chiu SK; Yang YS; Wang YC; Lin JC
J Microbiol Immunol Infect; 2012 Jun; 45(3):214-20. PubMed ID: 22571999
[TBL] [Abstract][Full Text] [Related]
19. Methicillin-resistant Staphylococcus aureus bacteremia: epidemiology, outcome, and laboratory characteristics in a tertiary referral center in the UK.
Lewis T; Chaudhry R; Nightingale P; Lambert P; Das I
Int J Infect Dis; 2011 Feb; 15(2):e131-5. PubMed ID: 21134776
[TBL] [Abstract][Full Text] [Related]
20. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
